HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis-Reference-Cited by-同舟云学术

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis

Published:2023-05 Issue: Volume:172 Page:98-105
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Bruce Shaina F.,Wu Sharon,Ribeiro Jennifer R.,Farrell Alex,Oberley Matthew J.,Winer Ira,Erickson Britt K.,Klc Tenley,Jones Nathaniel L.,Thaker Premal H.,Powell Matthew A.

Funder

GOG Foundation

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference38 articles.

1. Molecular genetics of endometrial carcinoma;Bell;Annu. Rev. Pathol.,2019

2. Uterine serous carcinoma: key advances and novel treatment approaches;Ferriss;Int. J. Gynecol. Cancer,2021

3. Personalized care in uterine cancer;Iglesias;Clin. Adv. Hematol. Oncol.,2012

4. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes;Alkushi;Int. J. Gynecol. Pathol.,2010

5. Role of immunohistochemistry to distinguish grade 3 endometrioid carcinoma and uterine serous carcinoma;Zaidi;Appl. Immunohistochem. Mol. Morphol.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human epidermal growth factor 2 (HER2) amplification in uterine serous carcinoma: an analysis of prognosis and immune microenvironment;Virchows Archiv;2024-07-29

2. Implementation of HER2 Testing in Endometrial Cancer, a Summary of Real-World Initial Experience in a Large Tertiary Cancer Center;Cancers;2024-05-31

3. Top advances of the year: Uterine cancer;Cancer;2024-04-15